Stimulation of iodide uptake by human chorionic gonadotropin in FRTL-5 cells: effects on sodium/iodide symporter gene and protein expression

Franco Arturi, Ivan Presta, Daniela Scarpelli, Jean-Michel Bidart, Martin Schlumberger, Sebastiano Filetti and Diego Russo

Dipartimento di Medicina Sperimentale e Clinica and Dipartimento di Scienze Farmacobiologiche, Università di Catanzaro ‘Magna Graecia’, 88100 Catanzaro, Italy, Dipartimento di Scienze Cliniche, Università ‘La Sapienza’, Rome, Italy and Institut Gustave Roussy, Villejuif, France

Abstract

Background: Various clinical and experimental findings support the concept that human chorionic gonadotropin (hCG) can stimulate iodide uptake in thyroid cells. Design: We investigated the molecular mechanisms underlying the effects of hCG on iodide uptake, and particularly its action on the expression of Na\(^{+}/I\(^{-}\) symporter (NIS) mRNA and protein.

Methods: Iodide uptake was analyzed in FRTL-5 cells by measuring \(^{125}\)I concentrations in cells after a 30-min exposure to 0.1 \(\mu\)Ci carrier-free Na\(^{125}\)I in the presence or absence of hCG or, for control purposes, TSH. Expression of NIS mRNA and NIS protein synthesis were evaluated, respectively, with a semiquantitative ‘multiplex’ RT-PCR method and Western blot analysis.

Results: Iodide uptake was increased by hCG in a dose- and time-dependent manner: maximal effects were observed after 72 h of stimulation. The effect was cAMP dependent and paralleled that of TSH, although it lacked the early cycloheximide-independent component seen with TSH, and its peak effect was lower. Semiquantitative multiplex RT-PCR revealed that hCG produced a significant increase in NIS mRNA levels that was detectable after 4 h and peaked after 48 h. In contrast, in TSH-stimulated FRTL-5 cells, maximum NIS mRNA expression was observed after 24 h of stimulation. Western blot analysis demonstrated that hCG also caused a 2.5-fold increase over basal values in NIS protein levels, which was similar to that observed after TSH stimulation although the peak effects of the latter hormone were less marked and occurred earlier.

Conclusion: Our data demonstrated that hCG stimulates iodide uptake in FRTL-5 cells by increasing NIS mRNA and protein levels. Thus, the functional status of the thyroid may be influenced by hCG-dependent changes in NIS expression occurring during pregnancy.

European Journal of Endocrinology 147 655–661
using the well-characterized FRTL-5 cell line. We found that hCG increases the levels of the NIS protein primarily through its effects on NIS gene expression, thus explaining the enhanced iodide uptake.

Materials and methods

Cell cultures

FRTL-5 cells were grown in 12-well tissue culture dishes for the measurement of $^{125}$I uptake and in 100 mm diameter dishes for both RNA and protein extraction. Coon’s modified Ham’s F-12 medium was supplemented with 5% calf serum, penicillin/streptomycin, amphotericin B and a six-hormone mixture containing bovine insulin (10 μg/ml), hydrocortisone (10$^{-8}$ mol/l), transferrin (5 mg/ml), somatostatin (10 μg/ml), glycly-histidyl-lysine (10 ng/ml) and bovine TSH (1 mU/ml), as previously described (13). Medium was replaced when cells reached 70–80% confluence. Prior to individual experiments, cells were maintained for 7 days in the same culture medium with all hormones except TSH.

$^{125}$I Uptake

$^{125}$I Uptake by FRTL-5 cells was measured as previously described (14). Briefly, cells were split and seeded into 12-well plates and, after aspiration of the culture medium, they were washed with 1 ml Hank’s balanced salt solution (HBSS) (Life Technologies S.r.l., San Giuliano Milanese, Milan, Italy) supplemented with Heps (10 mM, pH 7.3). $^{125}$I Uptake was initiated by adding to each well 500 μl buffered HBSS containing 0.1 μCi carrier-free Na $^{125}$I (Amersham Pharmacia Biotech, Colongo Monzese, Milan, Italy) and 10 μM NaI (Sigma-Aldrich S.r.l., Milan Italy) to obtain a specific activity of 20 mCi/mmol. In half of the wells, $^{125}$I was replaced when cells reached 70–80% confluence. Prior to individual experiments, cells were maintained for 7 days in the same culture medium with all hormones except TSH.

RNA extraction and semiquantitative RT-PCR

Total RNA was extracted from FRTL-5 cells using the RNA Fast Kit (Genenco; M-Medical, Florence, Italy) according to the manufacturer’s instructions. cDNA was synthesized from 1 μg total RNA, as previously described (15). The mixture was incubated at 25°C for 10 min, at 42°C for 60 min, heated to 99°C for 5 min, and then stored at −20°C. A semiquantitative multiplex RT-PCR was designed (16) to compare the RT-PCR products of the NIS gene with those of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene to determine their relative expression levels. PCR amplification was performed using 5 μl cDNA, and the samples were subjected to 32 cycles of amplification, as follows: cycle 1: denaturation at 95°C (10 min); cycles 2–31, each of which included denaturation at 95°C (30 s), annealing at 60°C (30 s) and extension at 72°C (30 s) for 30 cycles; cycle 32: 72°C for 7 min. Primer oligonucleotides for the rat NIS gene were: 5’ primer, 5’-GCTTGGGATGTGTACGTTT-3’ and 3’ primer, 5’-ACACTGACACCTTCTGGAGT-3’. The amplification yielded a 219 base pair DNA product whose sequence corresponded to that of fragment 1002–1220 of the rat NIS gene (9). Primer oligonucleotides for the rat GAPDH gene were: 5’ primer, 5’-TTACACCATGGAAGCCT-3’ and 3’ primer, 5’-ACAGCTGTCAGGAT-3’. The amplification yielded a 376 base pair DNA product corresponding to fragment 1147–1493 of the rat GAPDH gene, as reported in the Gene Bank (accession no. AF 106860).

To ensure that the amplification of both rat NIS and rat GAPDH remained within the exponential range, reaction conditions were optimized by assessing the variation in signal intensity for the two genes at various cycle numbers. Three different primer ratios were tested to achieve the same efficiency of amplification, and the ratio 1:1 was used (data not shown). The primers of rat GAPDH were added after the first 15 cycles of the reaction. Ten of the fifty microliters of amplification products were run on a 1.5% Tris–Borate–EDTA agarose gel containing ethidium bromide. The bands of the positive film were scanned, and the density and the width of each PCR product were measured using the NIH Image Program (Wayne Parlow and obtained through the National Hormone and Pituitary Program of the NIDDK) and with a commercial preparation of purified hCG (specific activity 14 000 IU/mg) purchased from Sigma-Aldrich S.r.l. As reported by Hershman et al. (5), there were no significant differences between the effects of these two preparations (data not shown). Therefore, in the experiments reported in this paper, the less costly commercial preparation was used for hCG stimulation. TSH, as well as ouabain, KCIO$_4$, forskolin, dibutyryladenosine 3’-5’-cyclic monophosphate ((Bu)$_2$ cAMP) and cycloheximide, were obtained from Sigma-Aldrich S.r.l.
Protein extraction and Western blot analysis

Total proteins were extracted from thyroid cell lines as previously described (16). Briefly, confluent cells from three Petri dishes were collected and homogenized in 1 ml buffer containing 250 mM sucrose, 10 mM Hepes–KOH (pH 7.5), 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml leupeptin and 10 μg/ml aprotinin. The homogenate was centrifuged at 14 000 g (4°C for 15 min), and the supernatant (which contained the whole cell lysate) was quantified spectrophotometrically using the Bradford method (17). Thirty micrograms of protein were loaded onto a 4–20% gradient SDS polyacrylamide gel and subjected to electrophoresis at a constant voltage (120 V). Electroblotting to a Hybond ECL-polyvinylidene difluoride nitrocellulose membrane (Amersham Pharmacia Biotech) was performed for 2 h at 12.5 mA using a Mini TRANS BLOT electroblotting system (Bio-Rad Laboratories S.r.l.). After 2 h of blocking at room temperature with TTBS/milk (Tris-buffered saline, 1% Tween 20, and 5% non-fat dry milk), the membrane was incubated overnight at 4°C in TTBS/milk with a 1/1000 dilution of affinity-purified rabbit anti-NIS (18, 19) polyclonal antibody or a 1/5000 dilution of mouse monoclonal anti-human β-actin antibody (Sigma-Aldrich S.r.l.). After one 5-min and two 5-min washes in TTBS, the membrane was incubated with a 1/2000 dilution of horseradish peroxidase-conjugated anti-rabbit or anti-mouse antibody (Amersham Pharmacia Biotech) in TTBS/milk. After one 15-min and two 5-min washes in TTBS, the protein was visualized with an enhanced chemiluminescence Western blot detection system (ECL-Plus; Amersham Pharmacia Biotech) and quantified by means of densitometric scanning.

Statistical analysis

Results are expressed as means±S.E.M. Differences between individual points of stimulation were evaluated by analysis of variance (one-factor ANOVA) followed by t-test. A level of P < 0.05 was considered statistically significant.

Results

Effects of hCG and TSH on iodide uptake

We first compared the effects of hCG and TSH on iodide uptake in FRTL-5 cells. In time-course experiments, iodide uptake in FRTL-5 cells that had been precultured for 7 days in the absence of TSH was enhanced by exposure to 1000 IU/ml hCG. The increased uptake was observed following a latency period of 8 h and peaked after 72 h of stimulation (Fig. 1A). Similar results were observed using 1 mIU/ml TSH, although the increase occurred earlier (after a 2-h latency period); as with hCG, the maximum effect was evident after 72 h of stimulation (Fig. 1B).

To determine whether the actions of the two hormones had been mediated by de novo protein synthesis, the FRTL-5 cells were grown in the presence or absence of 10 μg/ml cycloheximide, an inhibitor of protein synthesis. Cycloheximide completely abolished the hCG-induced stimulation of iodide uptake and, with the exception of early effects, also that produced by TSH (Fig. 1).

The effect of hCG was concentration dependent with detectable stimulation after the addition of 50 IU/ml

Figure 1 Effect of hCG (A) and TSH (B) on iodide uptake in FRTL-5 cells. Iodide uptake was measured as described in Materials and methods at the indicated hours after addition of 1000 IU/ml hCG (A) and 1 mIU/ml TSH (B) at time zero. Iodide uptake is expressed as the mean±S.E.M. of values obtained from three different experiments. Cycloheximide (CH) completely abolished the hCG-induced stimulation of iodide uptake and, with the exception of early effects (2 h), also that produced by TSH (see Materials and methods). *P = 0.001. **P < 0.001 (ANOVA followed by t-test).
hCG and maximal enhancement after exposure to 1000 IU/ml (Fig. 2). This effect was mimicked by 10 μM forskolin and by 1 mM (Bu)2 cAMP (data not shown). Finally, both the initial and steady-state phases of hCG-stimulated 125I uptake were inhibited by the anion KClO4 (Table 1) and by ouabain, which inhibits Na+–K+–ATPase (data not shown).

**Effects of hCG on NIS mRNA and protein levels**

The effect of hCG on NIS gene expression was then analyzed by using a multiplex semiquantitative RT-PCR. As shown in Fig. 3, time-course studies demonstrated an increase in NIS mRNA levels that was detectable after 4 h of hCG stimulation; peak levels (a 3.5-fold increase over basal values) were observed after 48 h (Fig. 3A). Again, a similar pattern of stimulation was observed in FRTL-5 cells stimulated with TSH: in this case, however, increased uptake was evident 2 h earlier, and the maximal effect was somewhat greater than that seen with hCG (Fig. 3B).

Western blot analysis of NIS protein showed that hCG increased the NIS protein level after 8 h of stimulation, with a 2.5-fold increase over the basal value after 24 h (Fig. 4A). Similar effects were seen in cells stimulated with cAMP analogs (data not shown) or with TSH, which produced higher peak uptake after 72 h of stimulation (Fig. 4B).

**Discussion**

It is well recognized that hCG possesses a thyroid-stimulating activity that influences thyroid function in normal pregnancy. At 10–12 weeks of gestation, when hCG peaks, there is a decrease in serum TSH levels. In pathological conditions, excessive hCG secretion may cause hyperthyroidism in patients (2). A high proportion of patients with hyperemesis gravidarum present evidence of increased thyroid function although few of them have clinical hyperthyroidism. Many patients with trophoblastic tumors, including benign hydatidiform moles and malignant choriocarcinomas, also show signs of hyperthyroidism, which is cured when the neoplasm is removed or subjected to effective chemotherapy. The mechanism underlying the thyrotropic effects of hCG is believed to be related to the close structural relationships between hCG and TSH and between their receptors. Moreover, a particular mutant TSH receptor has been described that is hypersensitive to hCG at normal concentrations (20).

A number of in vitro experiments also suggest that hCG’s effects on the thyroid are the result of its direct interaction with the TSH receptor (3, 4). In FRTL-5 rat thyroid cells, hCG has been demonstrated to increase cAMP, iodide transport, and cell growth (5, 21, 22) and, in cells transfected with the human TSH receptor, it increases cAMP production (4). The results of the present study confirm previous observations that hCG stimulates iodide uptake by thyrocytes. They also demonstrate that this effect parallels that of TSH but without the early, protein synthesis-independent stimulation observed with TSH. The action of hCG can, in

![Figure 2](image_url)
fact, be fully attributed to the increases it provokes in levels of NIS mRNA and the NIS protein itself. The increased iodide uptake induced by hCG was observed after a lag period of 8 h, which is compatible with the time requirements for a significant effect on NIS protein biosynthesis, and it was fully abolished by addition to the growth medium of the protein synthesis inhibitor, cycloheximide.

The central role of the NIS in mediating the thyrotropic effects of hCG is also supported by other observations. For example, the serum of pregnant women has been shown to exert thyroid-stimulating activity \textit{in vitro} (23), and iodide uptake is correlated with serum hCG levels during the first, but not the third, trimester of pregnancy (24). The NIS protein is also expressed in human placenta (25), and we have recently found that expression of the NIS gene in placental samples from the first trimester is, in fact, higher than that of third trimester samples (26). NIS gene expression parallels that of the hCG-B gene, and it is stimulated \textit{in vitro} by a cAMP analog (26). Thus, by acting on the expression of NIS in both thyroid and trophoblast cells, hCG modulates the uptake and transplacental passage of iodide, influencing both maternal

**Figure 3** Effects of hCG (A) and TSH (B) on NIS mRNA levels in FRTL-5 cells. FRTL-5 cells were grown in 100 mm diameter dishes in medium without hCG or TSH (see Materials and methods) and then exposed to 1000 IU/ml hCG (A) or 1 mIU/ml TSH (B) for the indicated periods of time. Total RNA was extracted from duplicate dishes of cells (as described in Materials and methods), and the levels of RNA were measured using a semiquantitative multiplex RT-PCR. Data are expressed as the mean ± S.E.M. of values obtained from at least three different experiments. *$P < 0.05$, **$P = 0.002$, ***$P < 0.001$ (ANOVA followed by t-test).

**Figure 4** Effect of hCG (A) and TSH (B) on NIS protein expression in FRTL-5 cells. Whole-cell protein extracts from FRTL-5 cells stimulated with 1000 IU/ml hCG (A) or 1 mIU/ml TSH (B) for the indicated periods of time were examined by Western blot analysis using a polyclonal anti-NIS antibody and a monoclonal anti-human \(\beta\)-actin antibody as described in Materials and methods. (a) Autoradiograph of a representative experiment. (b) Staining intensity is expressed as the mean ± S.E.M. of values obtained from two different experiments. Data are expressed relative to the control values (time 0). *$P < 0.05$, **$P < 0.001$ (ANOVA followed by t-test).
and fetal thyroid function in an early critical stage of pregnancy.

It has recently been reported that TSH stimulation of iodide uptake by FRTL-5 cells is mediated not only by increases in the transcription and biosynthesis of the NIS, but also by its targeting to and/or retention in the plasma membrane which is thought to be dependent upon protein phosphorylation (27). This might account for the dissociation observed in early studies between the magnitude of increase in iodide uptake and the amount of NIS protein found after TSH stimulation (28, 29), and it could also explain our observation of the incomplete abolition of TSH’s effects by the protein synthesis inhibitor cycloheximide. It thus appears that, at least in FRTL-5 cells, very low levels of NIS protein may be produced in the absence of TSH, although the presence of the hormone is probably required for the complete execution of NIS-mediated activities. In contrast, hCG’s effects develop much more gradually (8 h vs 2 h latency with TSH) and are completely abolished by cycloheximide. These findings indicate that, at least in vitro, TSH regulation of the delicate function of iodide uptake is a complex phenomenon, with early and late effects and both transcriptional and non-transcriptional mechanisms, whereas hCG is responsible only for longer-term effects that depend exclusively on the de novo synthesis of the NIS protein. These latter effects are likely to play an important role during pregnancy. Considering that many other factors, including iodide (30), estradiol (31, 32) and certain cytokines (11, 12), can also modify iodide uptake by acting on NIS expression, and that these factors are themselves subject to pregnancy related modifications, we feel that elucidation of the mechanisms that regulate NIS expression may help to clarify the pathogenesis of a number of thyroid disorders that are associated with pregnancy.

Acknowledgements

This work was supported by a grant to S F (MURST-Cofin 2000) and D R (MURST-Cofin 2000). We wish to thank Ms Marian Kent for editorial assistance.

References

2 Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocrine Reviews 1997 18 404–413.
23 Yoshimura M, Nishikawa M, Horimoto M, Yoshikawa N, Sawaragi S, Horokoshi Y et al. Thyroid-stimulating activity of


30 Eng PH, Cardona GR, Previti MC, Chin WW & Braverman LE. Regulation of the sodium/iodide symporter by iodide in FRTL-5 cells. *European Journal of Endocrinology* 2001 **144** 139–144.


Received 28 March 2002
Accepted 16 July 2002